Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.56 |
| ▸ | CRHBP | P24387 | 2/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | ALPG | P10696 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5508139 | 0.88 | CACNA1B (0.54) | CACNA1BALDH1A1HTR7KMT2AKDM4E | |
| SCHEMBL4277758 | 0.88 | CACNA1B (0.75) | CACNA1BALDH1A1KDM4E | |
| SCHEMBL4290517 | 0.87 | CACNA1B (0.60) | CACNA1BALDH1A1HTR7MEN1KMT2A | |
| SCHEMBL4285152 | 0.84 | SIGMAR1 (0.56) | CACNA1BALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL14997384 | 0.81 | HTR2A (0.61) | CACNA1BSMN1; SMN2 | |
| SCHEMBL4277843 | 0.80 | ACHE (0.55) | CACNA1BSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL4285276 | 0.79 | CHRM4 (0.56) | CACNA1B | |
| SCHEMBL4282387 | 0.78 | ALDH1A1 (0.51) | CACNA1BALDH1A1KDM4E | |
| SCHEMBL4280454 | 0.78 | CACNA1B (0.75) | CACNA1BALDH1A1KDM4E | |
| SCHEMBL4284277 | 0.77 | HTR2A (0.48) | CACNA1BSMN1; SMN2ALDH1A1LMNAHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000174-B2 | 4-phenylsulfonamidopiperidines as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2015-04-07 | — | — | US | disclosed |
| EP-1814851-B1 | 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS | EURO CELTIQUE SA (LU) | 2013-06-05 | — | — | EP | disclosed |
| US-20090105249-A1 | 4-phenylsulfonamidopiperidines as calcium channel blockers | EURO-CELTIQUE S.A. (LU) | 2009-04-23 | — | — | US | disclosed |
| CN-101044116-A | 4-phenylsulfonamidopiperidines as calcium channel blockers | EURO CELTIQUE SA (LU) | 2007-09-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105249-A1 | 4-phenylsulfonamidopiperidines as calcium channel blockers | CACNA1A, CACNA1E, CACNA1B | CACNA1B 3/4885CRHBP 1555/4885CRHR2 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.